StemCells raises cash, brings spinal cord injury study to US
This article was originally published in Clinica
Executive Summary
StemCells has $16.2m in new capital and plans to start two or three controlled Phase II clinical trials next year, but first the Newark, California-based company must finish two Phase I/II clinical trials evaluating its HuCNS-SC human neural stem cells.